Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931096 | 0.83 | CHEK1 (0.74) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931594 | 0.82 | CHEK1 (0.54) | CHEK1CCNA2CDK2CCNA1AURKA | |
| SCHEMBL14413581 | 0.81 | CHEK1 (0.52) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14413524 | 0.80 | CHEK1 (0.41) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931616 | 0.77 | CHEK1 (0.72) | CHEK1CCNA2CDK2CCNA1AURKA | |
| SCHEMBL15146197 | 0.76 | CHEK1 (0.63) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931082 | 0.75 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11938616 | 0.75 | CHEK1 (0.64) | CHEK1CCNA2CDK2CCNA1AURKA | |
| SCHEMBL11931614 | 0.75 | CHEK1 (0.64) | CHEK1CCNA2CDK2CCNA1AURKA | |
| SCHEMBL11931606 | 0.74 | CHEK1 (0.52) | CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7563798-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070072882-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072882-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CHEK1 60/4885CCNA2 29/4885CDK2 1/4885 |
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | CHEK1 8/4885CCNA2 1270/4885CDK2 64/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | CHEK1 8/4885CCNA2 1270/4885CDK2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.